a public good project by the
Synthesis
Company
of California

© 2026

Michael J. Cork | doi.page

0 works0 citations0 h-index

Michael J. Cork

Royal Hallamshire Hospital(GB)Sheffield Children's University(GB)Sheffield Teaching Hospitals NHS Foundation Trust(GB)Sheffield Children's NHS Foundation Trust(GB)Sheffield Children's Hospital(GB)University of Sheffield(GB)

Publications by Year

Research Areas

Dermatology and Skin Diseases, Allergic Rhinitis and Sensitization, Asthma and respiratory diseases, Food Allergy and Anaphylaxis Research, Urticaria and Related Conditions

Most-Cited Works

→ Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis(2016)1,987 cited
→ Adverse effects of topical glucocorticosteroids(2005)1,102 cited
→ A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1(2010)1,051 cited
→ Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity(2012)1,038 cited
→ Epidermal Barrier Dysfunction in Atopic Dermatitis(2009)751 cited
→ Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention(2014)710 cited

→ Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*(2020)

563 cited

→ New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene–environment interactions(2006)522 cited

→ Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t(2017)469 cited

→ Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial(2020)460 cited